How do you approach adjuvant therapy for a resected gastric GIST when the risk for recurrence is discordant between various prediction tools?

Topics: Sarcoma • Medical Oncology • GIST

For example, gastric GIST, < 5 mitoses/hpf and size > 5 cm but < 10 cm is intermediate by NIH criteria but low by NCCN/CAP criteria. The same tumor would have met inclusion criteria for adjuvant therapy in EORTC trial but is not "high risk."

Answer from: Medical Oncologist at Academic Institution

For intermediate risk patients, I generally have a discussion with the patient surrounding the risk of recurrence vs the potential toxicity of adjuvant therapy. Some patients will opt for surveillance and others will be more comfortable starting adjuvant imatinib. A nomogram that I find especially h...

Comments

Medical Oncologist at St Jude Heritage Medical Group
How about the "low risk" but a large gastric GIST,...

Related Questions